Boston Scientific (NYSE:BSX) is negotiating to buy three Israeli companies for $100 million, says the medical-technology company's CFO, Larry Best, according to Ma'ariv.
All the Israeli companies in question develop minimally-invasive medical applications.
Boston is meanwhile embroiled in a legal battle with another Israeli firm, the stent-maker Medinol. Entering into partnership with Medinol was the worst mistake Boston ever made, Best said. But he also added that the situation with Medinol is of no importance.